In this study, we provide evidence that plasma lipidomics can capture metabolic differences between patients with FH carrying pathogenic variants in heterozygosis in LDLR and those without identifiable genetic variants, even those of uncertain significance, reinforcing the role of sphingolipid metabolism in hypercholesterolemia and potentially in the related cardiovascular complications. This evidence concerns the gene LDLR and familial hypercholesterolemia.